<DOC>
	<DOCNO>NCT03077607</DOCNO>
	<brief_summary>This study patient advance solid tumor investigation P-gp inhibition induction PK talazoparib .</brief_summary>
	<brief_title>A Study Evaluate Effect Itraconazole Rifampin Pharmacokinetics Talazoparib Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>Subjects participate study clinically significant toxicity disease progression may eligible continue treatment separate extension protocol ( MDV3800-13 ) .</detailed_description>
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Talazoparib</mesh_term>
	<criteria>1 . Arm A : At least 18 year age &lt; 65 year age ( time point consent ) willing able provide inform consent . Arm B : At least 18 year age ( time point consent ) willing able provide inform consent . 2 . Histologically confirm advanced solid tumor ( limited platinumresistant ovarian carcinoma , cervical adenocarcinoma , small cell lung carcinoma triplenegative breast cancer ) judge Investigator appropriate standard therapy . 3 . ECOG performance status ≤ 2 screening time enrollment . 4 . Expected life expectancy ≥ 3 month . 5 . Able swallow study drug comply study requirement . 6 . Female subject may enrol consider childbearing potential , postmenopausal , childbearing potential use highly effective form contraceptive , female subject donate eggs time point investigational medicinal product ( IMP ) administration least 45 day thereafter . 7 . Males partner childbearing potential may enrol use condom sex pregnant woman woman childbearing potential , donate sperm time point study drug administration least 105 day thereafter , male donate sperm time point study drug administration least 105 day thereafter . 8 . Female subject must breastfeed screen study participation 45 day last dose study drug . 9 . Willingness ability comply schedule visit , treatment plan , laboratory test , trial procedure . 1 . Treatment within 14 day 5 half life prior dose type systemic anticancer therapy investigational agent , whichever longer 2 . Major surgery within 8 week screen . 3 . Serious accompany disorder impair organ function . 4 . Symptomatic impend spinal cord compression cauda equina syndrome . 5 . Nonhealing wound , ulcer , bone fracture , include pathological bone fracture cause preexistent pathological bone lesion . 6 . Known myelodysplastic syndrome . 7 . Subjects follow serology exclude : HBsAg+ antiHBc+ ; HCV+ ; HIV+ . 8 . Serious unstable medical condition interferes ability tolerate treatment assessment associate protocol . 9 . Gastrointestinal disorder affect absorption . 10 . Known hypersensitivity talazoparib capsule component . 11 . Any condition reason interfere ability participate study , cause undue risk , complicate interpretation safety data , opinion Investigator Sponsor ( e.g . noncompliance , excessive alcohol consumption , intake drug abuse unless drug medically indicate [ e.g . opiates pain relief ] .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>